Bright Minds Biosciences Inc. announced on May 13, 2025, positive findings from its DBA/2 mouse model study evaluating BMB-101. The study demonstrated a complete elimination of drop attacks in this preclinical model.
The DBA/2 mouse model is recognized as highly predictive of sudden unexpected death in epilepsy (SUDEP), a severe complication of epilepsy. These findings highlight BMB-101’s potential to address critical gaps in SUDEP prevention.
BMB-101 is a novel scaffold 5-HT2C Gq-protein biased agonist currently in a Phase 2 clinical trial for Absence Epilepsy and Developmental and Epileptic Encephalopathy (DEE). The preclinical results reinforce the therapeutic rationale for BMB-101 in treating severe neurological disorders.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.